Pneumonia

The US Food and Drug Administration (FDA) has cleared Vaxcyte’s infant Investigational New Drug (IND) application for VAX-24, its 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD).  The company plans to initiate the infant Phase II study in the second quarter of 2023, with topline safety, tolerability and immunogenicity data […]

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for VAX-24, Vaxcyte’s 24-valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease.  The decision was based on positive topline results from a Phase I/II proof-of-concept study, which evaluated the safety, tolerability and immunogenicity of VAX-24 in adults 18-64 years of age.  […]

Pharming Group has announced the topline results from two randomised, open label, controlled, pilot clinical trials of patients hospitalised with Covid-19 treated with Ruconest (recombinant human C1 inhibitor) for the prevention of severe SARS-CoV-2 infection. The primary endpoint in both studies was disease severity on the seven-point WHO ordinal scale on Day Seven.  In the US study, which had included […]

The PneumoLight campaign, in collaboration with Pfizer – and coinciding with World Pneumonia Day – will see 232 buildings and monuments from 48 different countries will be illuminated in blue. The project involves Dr. Catia Cilloniz, a researcher at the Hospital Clínic of Barcelona, the University of Barcelona (UB), the Barcelona Institute for Global Health (ISGLOBAL), […]